Date: 2015-04-15
Type of information: Recruitment of the first patient
phase: 1
Announcement: recruitment of the first patient
Company: OncoTherapy Science (Japan) Kyowa Hakko Kirin (Japan)
Product: KHK6640
Action
mechanism: monoclonal antibody. KHK6640 is a monoclonal antibody which selectively binds to pathological aggregates of amyloid beta peptide. Aβ aggregates are thought to be one of the major factors involved in pathogenesis of Alzheimer’s disease, and this antibody is expected to suppress the progression of the disease.
Disease: Alzheimer\'s disease
Therapeutic area: Neurodegenerative diseases
Country: Japan,
Trial
details: The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of KHK6640, given as a single dose in Japanese patients with Mild to Moderate Alzheimer\'s Disease (NCT02377713).
Latest
news: * On April 15, 2015, OncoTherapy Science announced that KHK6640, an anti-amyloid beta (Aβ) peptide antibody which was out-licensed from Immunas Pharma (a consolidated subsidiary of OncoTherapy) to Kyowa Hakko Kirin, has been administered to the first patient in phase I clinical trial in Japan following of the phase I clinical trial that was started in Europe last year (NCT02127476).
This clinical trial aims to confirm the safety and tolerability of this anti-Aβ peptide antibody in patients with mild to moderate Alzheimer’s disease.
